Defective functionality of HDL particles in familial apoA-I deficiency: Relevance of alterations in HDL lipidome and proteome

Journal of Lipid Research

Volumn 55, Issue 12, 2015, Pages 2509-2520

  Rached, Fabiana ^a,b   Santos, Raul D ^b   Camont, Laurent ^a   Miname, Marcio H ^b   Lhomme, Marie ^a   Dauteuille, Carolane ^a   Lecocq, Sora ^a   Serrano, Carlos V ^b   Chapman, M John ^a   Kontush, Anatol ^a  

^a INSERM   (France)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antioxidative activity; Apolipoprotein A I; Cellular cholesterol efflux; Familial deficiency; Genetics; HDL functionality; High density lipoprotein; Lipidomics

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C3; CHOLESTEROL; CHOLESTEROL ESTER; GLYCEROPHOSPHOLIPID; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPIDOME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEOME; TRIACYLGLYCEROL; APOA1 PROTEIN, HUMAN; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; PHOSPHOLIPID; SPHINGOLIPID; STOP CODON;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CHEMICAL COMPOSITION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPOALPHALIPOPROTEINEMIA; LIPID COMPOSITION; MALE; NONSENSE MUTATION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; BLOOD; BRAZIL; DEFICIENCY; FAMILY HEALTH; FEMALE; GENETICS; METABOLISM; STOP CODON;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEIN C-III; BRAZIL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CODON, NONSENSE; FAMILY HEALTH; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPOALPHALIPOPROTEINEMIAS; LIPOPROTEINS, HDL; LIPOPROTEINS, HDL3; MALE; PHOSPHOLIPIDS; SPHINGOLIPIDS; TRIGLYCERIDES;

EID: 84919740774     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M051631     Document Type: Article

References (35)

1. Schaefer, E. J., R. D. Santos, and B. F. Asztalos. 2010. Marked HDL deficiency and premature coronary heart disease. Curr. Opin. Lipidol. 21: 289-297.
2. Santos, R. D., E. J. Schaefer, B. F. Asztalos, E. Polisecki, J. Wang, R. A. Hegele, L. R. Martinez, M. H. Miname, C. E. Rochitte, P. L. Da Luz, et al. 2008. Characterization of high density lipoprotein particles in familial apolipoprotein A-I defi ciency. J. Lipid Res. 49: 349-357.
3. Iatan, I., A. Palmyre, S. Alrasheed, I. Ruel, and J. Genest. 2012. Genetics of cholesterol efflux. Curr. Atheroscler. Rep. 14: 235-246.
4. Sorci-Thomas, M. G., and M. J. Thomas. 2002. The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc. Med. 12: 121-128.
5. von Eckardstein, A. 2006. Differential diagnosis of familial high density lipoprotein deficiency syndromes. Atherosclerosis. 186: 231-239.
6. Camont, L., M. Lhomme, F. Rached, W. Le Goff, A. Negre-Salvayre, R. Salvayre, C. Calzada, M. Lagarde, M. J. Chapman, and A. Kontush. 2013. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, antiinflammatory, and antiapoptotic functionalities. Arterioscler. Thromb. Vasc. Biol. 33: 2715-2723.
7. Kontush, A., and M. J. Chapman. 2006. Functionally defective HDL: a new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol. Rev. 58: 342-374.
8. Kiss, R. S., N. Kavaslar, K. Okuhira, M. W. Freeman, S. Walter, R. W. Milne, R. McPherson, and Y. L. Marcel. 2007. Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects. Arterioscler. Thromb. Vasc. Biol. 27: 1139-1145.
9. Daniil, G., A. A. Phedonos, A. G. Holleboom, M. M. Motazacker, L. Argyri, J. A. Kuivenhoven, and A. Chroni. 2011. Characterization of antioxidant/anti-inflammatory properties and apoA-I-containing subpopulations of HDL from family subjects with monogenic low HDL disorders. Clin. Chim. Acta. 412: 1213-1220.
10. Ng, D. S., L. A. Leiter, C. Vezina, P. W. Connelly, and R. A. Hegele. 1994. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I defi ciency in a family with analphalipoproteinemia. J. Clin. Invest. 93: 223-229.
11. Rumsey, S. C., N. F. Galeano, Y. Arad, and R. J. Deckelbaum. 1992. Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins. J. Lipid Res. 33: 1551-1561.
12. Chapman, M. J., S. Goldstein, D. Lagrange, and P. M. Laplaud. 1981. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J. Lipid Res. 22: 339-358.
13. Kontush, A., S. Chantepie, and M. J. Chapman. 2003. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23: 1881-1888.
14. Hansel, B., P. Giral, E. Nobecourt, S. Chantepie, E. Bruckert, M. J. Chapman, and A. Kontush. 2004. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab. 89: 4963-4971.
15. Guérin, M., P. J. Dolphin, and M. J. Chapman. 1994. New in-vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass-transfer between HDL and apoB-containing lipoprotein subspecies - identification of preferential cholesteryl ester accepters in human plasma. Arterioscler. Thromb. 14: 199-206.
16. Catalano, G., Z. Julia, E. Frisdal, B. Vedie, N. Fournier, W. Le Goff, M. J. Chapman, and M. Guerin. 2009. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler. Thromb. Vasc. Biol. 29: 268-275.
17. Lagrost, L. 1994. Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. Biochim. Biophys. Acta. 1215: 209-236.
18. Guérin, M., E. Bruckert, P. J. Dolphin, G. Turpin, and M. J. Chapman. 1996. Fenofi brate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 16: 763-772.
19. Guerin, M., P. Egger, C. Soudant, W. Le Goff, A. van Tol, R. Dupuis, and M. J. Chapman. 2002. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis. 163: 287-296.
20. Larijani, B., D. L. Poccia, and L. C. Dickinson. 2000. Phospholipid identification and quantification of membrane vesicle subfractions by 31P-1H two-dimensional nuclear magnetic resonance. Lipids. 35: 1289-1297.
21. Quehenberger, O., and E. A. Dennis. 2011. The human plasma lipidome. N. Engl. J. Med. 365: 1812-1823.
22. Quehenberger, O., A. M. Armando, A. H. Brown, S. B. Milne, D. S. Myers, A. H. Merrill, S. Bandyopadhyay, K. N. Jones, S. Kelly, R. L. Shaner, et al. 2010. Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res. 51: 3299-3305.
23. Larrede, S., C. M. Quinn, W. Jessup, E. Frisdal, M. Olivier, V. Hsieh, M-J. Kim, M. Van Eck, P. Couvert, A. Carrie, et al. 2009. Stimulation of cholesterol effl ux by LXR agonists in cholesterolloaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler. Thromb. Vasc. Biol. 29: 1930-1936.
24. Fournier, N., V. Atger, A. Cogny, B. Vedie, P. Giral, A. Simon, N. Moatti, and J. L. Paul. 2001. Analysis of the relationship between triglyceridemia and HDL-phospholipid concentrations: consequences on the efflux capacity of serum in the Fu5AH system. Atherosclerosis. 157: 315-323.
25. Nobécourt, E., S. Jacqueminet, B. Hansel, S. Chantepie, A. Grimaldi, M. J. Chapman, and A. Kontush. 2005. Defective antioxidative activity of small, dense HDL particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycemia. Diabetologia. 48: 529-538.
26. Kontush, A., E. C. de Faria, S. Chantepie, and M. J. Chapman. 2005. A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis. 182: 277-285.
27. Zerrad-Saadi, A., P. Therond, S. Chantepie, M. Couturier, K-A. Rye, M. J. Chapman, and A. Kontush. 2009. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 29: 2169-2175.
28. Kontush, A., and M. J. Chapman. 2010. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr. Opin. Lipidol. 21: 312-318.
29. Abbott, C. A., M. I. Mackness, S. Kumar, A. J. Boulton, and P. N. Durrington. 1995. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15: 1812-1818.
30. Davidson, W. S., R. A. G. D. Silva, S. Chantepie, W. R. Lagor, M. J. Chapman, and A. Kontush. 2009. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 29: 870-876.
31. Campos, E., and W. J. McConathy. 1986. Distribution of lipids and apolipoproteins in human plasma by vertical spin ultracentrifugation. Arch. Biochem. Biophys. 249: 455-463.
32. Zhao, Y., D. L. Sparks, and Y. L. Marcel. 1996. Effect of the apolipoprotein A-I and surface lipid composition of reconstituted discoidal HDL on cholesterol efflux from cultured fibroblasts. Biochemistry. 35: 16510-16518.
33. Taha, T. A., T. D. Mullen, L. M. Obeid. 2006. A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim. Biophys. Acta. 1758: 2027-2036.
34. Khera, A. V., M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M. F. Burke, K. Jafri, B. C. French, J. A. Phillips, M. L. Mucksavage, R. L. Wilensky, et al. 2011. Cholesterol effl ux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364: 127-135.
35. Li, X. M., W. H. Tang, M. K. Mosior, Y. Huang, Y. Wu, W. Matter, V. Gao, D. Schmitt, J. A. Didonato, E. A. Fisher, et al. 2013. Paradoxical association of enhanced cholesterol effl ux with increased incident cardiovascular risks. Arterioscler. Thromb. Vasc. Biol. 33: 1696-1705.